Atlas Venture, a Cambridge, MA-based early stage venture capital firm, hired Jodie Morrison as a venture partner.
Morrison will work with the Atlas team to build transformative new biotech companies.
Morrison is an executive and board member who most recently served as CEO of Cadent Therapeutics, which Atlas Venture formed and which was acquired by Novartis in 2021. Prior to Cadent, Morrison served as interim chief executive officer at Keryx Biopharmaceuticals, Inc. where she led the the merger with Akebia Therapeutics, and as acting chief operating officer at Syntimmune which was acquired by Alexion. Before that, Morrison served as president and chief executive officer of Tokai Pharmaceuticals, Inc. where she led the 2014 IPO and 2016 merger, and held other senior positions including chief operating officer and VP/head of clinical and program operations. Earlier in her career, Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc.
She serves on the boards of several biotech companies.
Atlas Venture is a biotech venture capital firm that works side by side with scientists and entrepreneurs to translate high impact science into medicines for patients. Its seed-led venture creation strategy selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
FinSMEs
14/07/2021
Contacts
Kristen Margeson
Senior Director of Investor Relations and Marketing
Atlas Venture
[email protected]